The skin, the body's largest organ, serves as a highly effective barrier—primarily due to the stratum corneum, a thin 10–20 µm layer that blocks over 90 percent of substances—making topical drug delivery particularly difficult. Conventional formulations while user-friendly, face major challenges such as poor skin penetration, susceptibility to environmental degradation, and inability to deliver drugs in a sustained manner. These limitations result in reduced therapeutic effectiveness and poor patient compliance. Recent advancements in nanotechnology have led to the development of vesicular drug delivery systems (VDDS), which are nanoscale, lipid-based carriers capable of traversing the stratum corneum to deliver active agents more effectively into deeper layers of the skin. VDDS improve drug absorption, protect sensitive molecules from degradation, enable sustained and targeted drug release, and minimize systemic exposure and side effects. VDDS are broadly classified into lipoidal and non-lipoidal carriers, each possessing distinct advantages and limitations. Lipoidal vesicles—such as liposomes, transferosomes, and ethosomes—mimic biological membranes and promote efficient dermal and transdermal delivery; however, they can be prone to oxidation, leakage, and require more complex and costly production. Non-lipoidal carriers— including niosomes, bilosomes, and aquasomes—offer better chemical stability and are well-suited for oral and protein-based therapeutics, though they may exhibit lower encapsulation efficiency and require precise formulation control. Drug release from VDDS occurs via mechanisms such as passive diffusion, osmotic pressure gradients, pHtriggered destabilization in acidic environments, and external stimuli like temperature or light to achieve localized, controlled delivery. In topical applications, VDDS have shown effectiveness across multiple conditions, including antimicrobial therapy, treatment of psoriasis and eczema, acne management, local anti-inflammatory interventions, and localized cancer therapy. Innovative developments—such as nanoparticle incorporation, stimuli-responsive ("smart") vesicles, gene delivery systems, and co-delivery of multiple therapeutics—promise to overcome pharmacokinetic challenges, enhance targeting precision, and reduce toxicity, positioning VDDS as a promising frontier in topical drug delivery.